Nortech Labs – SibutraTech 30

Nortech Labs SibutraTech 30 contains Sibutramine HCL, a centrally acting appetite suppressant originally developed for the medical management of obesity.

Sibutramine works by inhibiting the reuptake of serotonin and norepinephrine, helping increase feelings of fullness and reduce hunger. This mechanism may contribute to reduced calorie intake and weight loss.

Although previously prescribed for weight management, Sibutramine was withdrawn from several major markets because of increased cardiovascular risks, including heart attack and stroke. It is not considered a routine or low-risk weight-management treatment.

➤ KEY BENEFITS

→ Appetite Suppression: Reduces hunger signals through its effects on neurotransmitter activity

→ Satiety Support: May increase feelings of fullness after meals

→ Calorie Intake: Can help reduce food consumption through appetite regulation

→ Weight Management: Historically used as part of medically supervised obesity treatment

→ Non-Hormonal: Does not act as an anabolic steroid or androgen

→ Oral Formulation: Presented in tablet form

➤ POSSIBLE SIDE EFFECTS

Sibutramine can cause significant cardiovascular and neurological adverse effects.

→ Increased blood pressure

→ Elevated heart rate or palpitations

→ Dry mouth and constipation

→ Insomnia, restlessness, or anxiety

→ Headaches or dizziness

→ Excessive sweating

→ Increased risk of serious cardiovascular events, including heart attack and stroke

Important: Sibutramine was withdrawn from the US and European markets because its cardiovascular risks outweighed its weight-loss benefits. It may also cause serotonin syndrome when combined with certain antidepressants or other serotonergic medications.

➤ DOSAGE & ADMINISTRATION

⇨ Administration: Oral Tablets

⇨ Product Strength: 30 mg per Tablet

⇨ Historical Medical Dosage: Previously prescribed at 10–15 mg once daily in markets where it was authorised.

⇨ Supplied Dosage Range: 15–30 mg per day (manufacturer-provided information; not a recommended dosage)

⇨ Half-Life: Approximately 14–16 hours for its active metabolites

⇨ Treatment Duration: No established safe cycle duration for this 30 mg formulation.

Important: The supplied 30 mg tablet strength exceeds the historical maximum approved daily dose of 15 mg. The proposed beginner, intermediate, and advanced protocols should not be treated as safe dosing guidance. Breaking a tablet in half also does not establish that it is suitable for dose splitting.

➤ PRODUCT SPECS

⇨ Substance: Sibutramine Hydrochloride

⇨ Active Dosage: 30 mg per Tablet

⇨ Classification: Centrally Acting Appetite Suppressant

⇨ Category: Oral / Weight Management

⇨ Form: 30 Tablets × 30 mg

⇨ Half-Life: Approximately 14–16 hours (active metabolites)

⇨ Water Retention: Not a typical effect

⇨ Acne: Not a typical effect

⇨ High Blood Pressure: Yes, significant risk

⇨ Aromatization: No

⇨ Hepatotoxicity: Rare liver injury has been reported

⇨ Regulatory Status: Withdrawn from several major markets due to cardiovascular safety concerns